Page 28 - Pfizer

India Coronavirus Dispatch: What does '90% efficacy' for a vaccine mean?

Students aspiring to study abroad may face tougher competition in 2021, AstraZeneca's manufacturing error casts doubt over its potential, and other news relevant to India's fight against the pandemic

Malaysia secures Pfizer Covid-19 vaccine in a first for Southeast Asia

Many Asian countries are not betting on it partly due to tropical heat, remote island communities and a lack of ultra-cold freezers

India Coronavirus Dispatch: Situation remains grim in national capital

Covid may impact vision of some patients, ethical dilemma of denying vaccine to trial participants, UP artisans start selling online-news relevant to India's fight against the pandemic

Explainer: When and how will Covid-19 vaccines become available?

If regulators approve any of the vaccines in coming weeks, the distribution could begin almost immediately

BioNTech, Fosun start Phase II trial of Covid-19 vaccine in China

BioNTech is also working with U.S. pharma giant Pfizer on the vaccine

Not working with any other partner for Covid-19 vaccination, says Pfizer

Clarification comes after a Mumbai-based tour operator announces 'vaccine tourism', solicits customer interest

Affordable Covid-19 vaccines will test world's intellectual property regime

An intellectual property regime that is not flexible enough to manage the coronavirus crisis is one that will break under the weight of that techno-dystopia.

India faces cold chain logistics challenge for Covid-19 vaccination

The nation with the world's second-highest infections plans to use the existing cold chain network in place for its Universal Immunization Program

UK regulator begins reviewing Pfizer-BioNTech coronavirus vaccine data

The UK is expected to receive a total of 40 million doses by the end of 2021, enough to vaccinate up to a third of the population, with the majority of doses anticipated in the first half of next year

Astra-Oxford Covid-19 vaccine works but doses could be in short supply

Pfizer and Moderna may have an initial advantage in dealing with manufacturing challenges, as their novel messenger RNA technology can be scaled up.

Pfizer Covid-19 vaccine could get UK approval this week, says report

Britain formally asked its medical regulator, the MHRA, last week to assess the suitability of the Pfizer-BioNTech vaccine

Russia's Covid-19 vaccine price to be lower than those of Pfizer, Moderna

The price per dose of the Russian coronavirus vaccine Sputnik V will be much lower than that of the vaccines of US drug giants Pfizer and Moderna, said the Russian vaccine's official Twitter account

India to Brazil, Astra-Oxford vaccine is key to many nations' Covid plan

The Astra vaccine costs a fraction of the price set by Pfizer; it should be easier to deploy far and wide than other shots.

Pfizer, BioNTech seek emergency use of coronavirus shots in US

Pfizer asked US regulators to allow emergency use of its COVID vaccine, starting clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic

Pfizer seeking emergency use of its Covid-19 vaccine in US

The action comes days after Pfizer Inc and its German partner BioNTech announced that its vaccine appears 95% effective at preventing Covid-19

How sophisticated mRNA vaccines from Pfizer, Moderna are and how they work?

Pfizer-BioNTech vaccine candidate, BNT162b2, was 90% effective in preventing infection during the phase 3 clinical trial, which enrolled 43,538 participants, with 30% in U.S. and 42% abroad

World Coronavirus Dispatch: Rapid vaccine production the real challenge

Covid-19 shakes up world's most expensive cities, how four Canadian provinces have protected their people, Italy runs short of ICU staff and other pandemic-related news across the globe

Covid vaccine with no 'serious side-effects', but India faces cold-reality

Global drugmakers Pfizer and BioNTech have said that their Covid-19 vaccine was found 95 per cent effective in the final analysis of the Phase 3 trial, including in people aged over 65 years, paving the way for the companies to apply for emergency authorisation from US regulators within days. Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021. The major announcement comes just two days after leading biotechnology company Moderna said on Monday its virus vaccine had an efficacy rate of 94.5 per cent. But will the Pfizer vaccine be available in India? Watch the video >

Pfizer-BioNTech's Covid-19 vaccine deliveries may start before Christmas

(Reuters) - Pfizer Inc and BioNTech <22UAy.DE> could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.

Pfizer, Moderna Covid-19 vaccines may be authorised for use within weeks

States and territories are prepared to begin distributing the vaccines within 24 hours of receiving regulatory authorization